These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 33900817)

  • 1. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry.
    Saito M; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):157-162. PubMed ID: 35736625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Antihuman Killer Cell Lectin-Like Receptor Subfamily G Member 1 Monoclonal Antibodies for Flow Cytometry.
    Asano T; Nanamiya R; Tanaka T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):76-80. PubMed ID: 33900816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
    Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
    Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
    Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
    Cancer Biol Med; 2024 May; 21(6):451-72. PubMed ID: 38801082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
    Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
    Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
    Esen F; Deniz G; Aktas EC
    Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow Cytometry.
    Nanamiya R; Takei J; Asano T; Tanaka T; Sano M; Nakamura T; Yanaka M; Hosono H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):101-106. PubMed ID: 34161159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT as an emerging immune checkpoint.
    Harjunpää H; Guillerey C
    Clin Exp Immunol; 2020 May; 200(2):108-119. PubMed ID: 31828774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity.
    Han D; Xu Y; Zhao X; Mao Y; Kang Q; Wen W; Yu X; Xu L; Liu F; Zhang M; Cui J; Wang Z; Yang Z; Du P; Qin W
    Biochem Biophys Res Commun; 2021 Jan; 534():134-140. PubMed ID: 33341068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
    Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
    Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
    Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
    J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
    Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.